Evidence-based · Educational only
36+ Peptides indexed
Free research library
Free newsletter — subscribe below
★ = FDA-approved medical indication
Not medical advice — always consult a clinician
Evidence-based · Educational only
36+ Peptides indexed
Free research library
Free newsletter — subscribe below
★ = FDA-approved medical indication
Not medical advice — always consult a clinician
All peptides

CJC-1295 + Ipamorelin

Also known as: GH secretagogue blend (no-DAC)
Research / Investigational

CJC-1295 (no-DAC) is a modified GHRH analog; combined with the selective GH secretagogue ipamorelin to study synergistic GH pulse amplification.

Buy CJC-1295 + Ipamorelin on American Peptides

Affiliate link — we may earn a commission at no extra cost to you.

Overview

CJC-1295 (no-DAC) is a modified GHRH analog; combined with the selective GH secretagogue ipamorelin to study synergistic GH pulse amplification.

FDA Approval Status

Not approved by the FDA. Investigational or intended for research purposes only.

Mechanism of Action

GHRH-receptor activation (CJC-1295) with ghrelin-receptor agonism (ipamorelin).

Current Research

Individual peptides studied; combination widely used off-label in research settings.
Research strength: Preliminary

Potential Medical Uses

  • Investigational only

Potential Benefits

  • Amplified endogenous GH pulses (research)

Known Side Effects

  • Injection-site reactions
  • Water retention
  • Head-rush at dosing

Contraindications

  • Active malignancy
  • Pregnancy

Drug Interactions

  • Insulin/insulin secretagogues (theoretical)

Administration Methods

  • Subcutaneous injection (research)

Half-life

CJC-1295 no-DAC ~30 min; ipamorelin ~2 h

Reconstitution

Bacteriostatic water; concentration varies.

Storage & Handling

Refrigerated reconstituted; use within ~30 days.

References & Sources

Frequently Asked Questions

Information on this page is educational and general in nature. It is not medical advice. Consult a qualified healthcare professional before making any medical decisions.